News & Evens


BiOptic has certificated by UL in conformance with FDA 21 CFR Part 11

The software system of Qsep series bio-fragment analyzer, Q-Analyzer, which is developed by BiOptic, has certificated by UL in conformance with FDA 21 CFR Part 11 in Jan 2021. The FDA guidelines for Data Integrity include the requirement for compliance for the storage of electronic records.

BiOptic - Surveillance Pooling Test models

The Centers for Disease Control and Prevention (CDC) in the US has suggested a monitoring method - surveillance pooling test, which divides a large group into several small groups, and the samples of each group are mixed into one sample for testing and analysis; if a positive result has shown up in a group, the members of this group will conduct further tests individually. This method got the advantages of testing large groups with a small number of samples and at a lower cost, which is very suitable for schools, factories, communities, companies, and other units. The suggested testing process is continuously every 1 to 2 days, in order to find out the COVID-19 carrier and take steps before the situation worsens.

ON-DEMAND WEBINAR: Rapid, Automated and High-Resolution Nucleic Acid Quality Control Solutions for Next-Generation Sequencing (NGS) using Capillary Electrophoresis (CE) approach

BiOptic will show how Qsep series bio-fragment analyzer support researchers on quality check during the NGS workflow by using capillary electrophoresis (CE) approach.

Office Relocation Notice

Thanks for the efforts of our distributors all over the world. Although COVID-19 crushes the world economy, BiOptic is still growing while facing this pandemic. Due to the increasing number of orders, our production efficiency almost reaches its limit, so we decided to enlarge the space of our production line to fulfill the market demand. The headquarter of BiOptic Inc. will be relocated to the next building beside our existing ones from 12/19 to 12/20.

BiOptic Inc. won A+ Industrial Innovation R&D Program

Congratulations! BiOptic won the A+ Industrial Innovation R&D Program

Celebration!BiOptic Inc. obtains a new European patent!

European Invention Certification No. 2609420

2020 BiOptic Web Conference

For gathering every distributor/partner around the world together and letting BiOptic to share more information about our new products and functions under the threat of COVID-19, BiOptic will have our 2020 distributor meeting as a Web Conference!

For different time zone, we have two sessions you could choose.
+ Sep. 29th, 2020
+ Oct. 14th, 2020

The web conference registration is opening. Regist and join us now!

2020 BiOptic Inc. Summer Internship Activity Started!

BiOptic Inc.’s internship program is to enable future biotech newbies to learn the practice of the biotechnology industry

BiOptic won the 2020 Taipei Biotechnology Award for Innovative Technology

During the Bio Asia-Taiwan exhibition, BiOpic Inc. demonstrated that the "Mobile Laboratory-Portable Pathogen Detection Platform" provides a complete solution for molecular detection in real-time, on-site and one-stop service, and won the 2020 Taipei Biotechnology Award for Innovative Technology.

BiOptic has launched ApoE detection kit

After multiple meat identification reagent kits, BiOptic Inc. has launched another molecular testing product this year-Alzheimer’s disease detection reagent kit; there is currently no definite drug to treat Alzheimer’s disease. A disease that consumes a lot of social resources, but if you can know in advance whether your genotype is a high-risk group for Alzheimer's disease, and change your living habits and diet early, you can reduce the risk of Alzheimer's disease.